[18F]florbetaben has been granted a Fast Track designation for cardiac amyloidosis, which will expedite the development of [18F]florbetaben for this indication [18F]florbetaben previously received orphan drug status as a diagnostic for the management of AL amyloidosis in EU and US The…
![Life Molecular Imaging Secures FDA Fast Track Designation for [18F]Florbetaben in Diagnosing Cardiac AL and ATTR Amyloidosis](https://cardiacvascularnews.com/wp-content/uploads/2025/01/Life-molecular-imaging-e1737489511884-90x60.png)